

Patient ID SA00147839	Patient Name VALIDATIONSOF, CIB	Birth Date 1951-02-14	Gender F	Age 70
Order Number SA00147839	Client Order Number SA00147839	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 17 Sep 2021 10:00		

Cutaneous Direct IFA, Biopsy

Interpretation

1 MCR

A. Left leg, skin punch biopsy, Immunofluorescence:

IgG: Negative

IgG4: Negative

IgM: Negative

IgA: Granular deposition within the walls of many superficial dermal vessels

C3: Negative

Fibrinogen: Negative

Impression:

Vascular fluorescence pattern consistent with IgA vasculitis
(see comment)

Comment:

The granular deposition of IgA within the walls of many superficial dermal vessels is consistent with IgA vasculitis. IgA vasculitis may be seen in leukocytoclastic vasculitis in the setting of Henoch Schonlein purpura, inflammatory bowel disease, autoimmune connective tissue disorders(Sjogren's syndrome, rheumatoid arthritis, lupus erythematosus and

spondylarthropathies), malignancy (including lymphoma and multiple myeloma), urticarial vasculitis, and as a reaction to medications (Magro CM et al. J Am J Dermatopathol, 1999; m21(3); 234–240; as well as in the context of a lymphocytic vasculopathy in the setting of a pigmented purpuric dermatosis, Dego's disease and lupus panniculitis (Crawson AN et al. J Cutan Pathol, 2002; 29: 596–601). Rarely granular deposition of IgA within cutaneous vascular walls may be seen in nonlesional skin biopsies of patients with IgA nephropathy and dermatitis herpetiformis. A final definitive diagnosis should therefore be based on correlation of the direct immunofluorescence findings with the clinical presentation, histopathological findings on examination of sections from formalin-fixed, paraffin-embedded tissue and other diagnostic tests.

Report electronically signed by

MCR

CAMERON MILLER

Case Number

MCR

DR-21-50

Received: 20 Sep 2021 15:13

Reported: 20 Sep 2021 15:18

Laboratory Notes

- 1 This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292

Report Status: Final